FTC Denies Violations In Watson Pay-To-Delay Probe

Law360, New York (July 22, 2010, 7:34 PM EDT) -- The Federal Trade Commission argued Thursday that it did nothing wrong in its antitrust investigation of a patent settlement between Watson Pharmaceuticals Inc. and Cephalon Inc., in a suit seeking to force Watson CEO Paul M. Bisaro to testify in the probe.

The FTC denied that it had attempted to “broker a deal” between Watson and rival Apotex Inc. or disclosed confidential information during the investigation, and asked the U.S. District Court for the District of Columbia to enforce a subpoena against Bisaro.

In 2009, the...
To view the full article, register now.